Researchers report they have identified a vaccine candidate for COVID-19 and are working towards phase one clinical testing. A chimpanzee adenovirus vaccine vector was chosen as the most suitable vaccine technology for SARS-CoV-2 as it can generate a stronger immune response in one dose and is not a replicating virus.